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 Implication for health policy/practice/research/medical education:
Epidemiological studies have suggested a linkage between alanine aminotransferase (ALT) levels and hepatic ﬁbrosis or hepato-
cellularcarcinoma (HCC) in hepatitis C virus (HCV) carriers. However, clinical features of HCV carriers with persistent normal ALT 
levels (PNALT) are not fully elucidated. This review focuses on the PNALT in HCV carriers and clinical signiﬁcance of hepatic ﬁbrosis 
in these carriers in order to bring out some common opinions on how to manage such HCV carriers with PNALT.
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Hepatitis C virus (HCV) infection causes chronic hepatitis, which frequently leads to he-
patic ﬁbrosis and hepatocellular carcinoma (HCC). Alanine aminotransferase (ALT) is a 
biomarker of hepatocyte injury and is associated with the progression of hepatic ﬁbro-
sis. Advanced hepatic ﬁbrosis also predisposes HCV carriers to a risk of HCC. In contrast, 
some cases with persistent HCV infection have normal ALT levels that persist for a long 
time, and these HCV carriers have no or mild hepatitis and hepatic ﬁbrosis. These HCV 
carriers are deﬁned as persistent normal ALT (PNALT) cases and their risk of HCC is low 
compared to HCV carriers with abnormal ALT. However, there are various deﬁnitions of 
normal ALT and PNALT, and advanced hepatic ﬁbrosis may be missed without a liver bi-
opsy. In addition, there is also a risk of ALT elevation in HCV carriers with PNALT, which 
increases the risk of progression to hepatic ﬁbrosis and HCC. Most HCV carriers with 
PNALT have asymptomatic or nonspeciﬁc symptoms. HCV carriers with PNALT are also 
considered to be responsive to interferon-based treatment. Thus, assessment of hepatic 
ﬁbrosis is important in HCV carriers, and the eradication of HCV infection is more likely 
in HCV carriers with evidence of hepatic ﬁbrosis, regardless of their ALT levels.
Copyright  c 2012 Kowsar M. P. Co. All rights reserved. 
1. Context
Hepatitis C virus (HCV) causes chronic hepatitis, liver 
cirrhosis, and hepatocellular carcinoma (HCC) at high 
rates (1-3). However, some cases remain asymptomatic 
with normal levels of alanine aminotransferase (ALT) af-
ter HCV infection and detection of the infection in these 
cases may only occur through screening, such as with 
an anti-HCV antibody test. The ALT level usually rises in 
hepatitis (4), but it is normal in approximately 20-30% 
of HCV carriers (5, 6). Previous studies have shown that 
elevated ALT levels predict an increased rate of HCV-
associated HCC in a community-based population and 
that serial measurements to identify persistent ALT ab-
normality may be useful in determining the HCC risk (7, 
8). Thus, HCV carriers with normal ALT levels were previ-
ously not indicated for antiviral therapy. In contrast, it 
has been shown that hepatic inﬂammation and ﬁbrosis 
are histologically present in many HCV carriers, even 
though their ALT level is normal, and these HCV carriers 
are candidates for antiviral therapy. These conﬂicting is-
sues may arise from ambiguity around the deﬁnition of 
normal ALT and with the natural course of HCV carriers 
with persistent normal ALT (PNALT). In this review, which 
is based on a search for articles using terms such as per-
sistent ALT, normal ALT, and HCV, we describe the charac-
teristics, natural course, and treatment in HCV carriers 
with PNALT. 78
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2. Evidence Acquisition
2.1. Epidemiologic Features of HCV Carriers
Many HCV carriers are asymptomatic. According to 
American Association for the Study of Liver Diseases 
(AASLD) practice guidelines, drug users, patients with a 
high risk for HCV infection (patients with HIV infection 
or hemophilia treated with coagulation factor prepara-
tions before 1987, and patients with hemodialysis or ALT 
abnormality), patients who received blood transfusion 
or organ transplantation before July 1992, children born 
to HCV-infected mothers, medical workers exposed to 
needles used for HCV-infected patients or to the mucosa 
of HCV-infected patients, and people who have had a sex-
ual relationship with an HCV carrier should be screened 
for a HCV infection (9). More than 170 million people 
worldwide are thought to be infected with the HCV. HCV 
infection progresses to a chronic state in 60-85% of infect-
ed people and may develop into liver cirrhosis and HCC 
after 20-35 years (3, 10). Poynard et al. reported that 33% 
of patients with a HCV infection had an expected median 
time to cirrhosis of less than 20 years without treatment 
(11). Other studies have also shown a rate of progression 
to cirrhosis of between 1.5 and 16 years following blood 
transfusion in approximately 20% of cases (12). The rate 
of progression to HCC was reported to be approximately 
2% per year (13, 14). In addition, about 1.4 million people 
(approximately 1% of HCV carriers) are estimated to die 
annually due to liver cirrhosis or HCC (1, 3). We previous-
ly reported that 70 out of 758 HCV carriers died due to a 
liver-related cause over an average of 8.2 years of follow-
up (a rate of 1% per year) (8). The important point is that 
those rates may be mainly due to the diversity in the de-
sign of the studies themselves. Host factors and environ-
mental factors aﬀect the progression of hepatic inﬂam-
mation and ﬁbrosis. Host factors include; advanced age 
at the time of infection, male gender, excess alcohol con-
sumption, excess iron intake, cigarette smoking, obesity, 
complications with diabetes, fatty liver and metabolic 
syndrome, and coinfection with human immunodeﬁ-
ciency virus (HIV), hepatitis B virus (HBV), and Schistoso-
miasis (3, 15). In addition, hepatic ﬁbrosis in liver grafts 
shows rapid progression after liver transplantation in 
hepatitis C patients (16, 17), although the mechanism for 
this remains unclear. In contrast, the progression of he-
patic ﬁbrosis may not be associated with HCV genotype 
or viral load (11, 18).
2.2. The Concept of ALT Normality and Deﬁnition for 
PNALT
Since ALT is released into the blood when the hepato-
cyte membrane is impaired or hepatocytes are destroyed, 
elevation of the serum ALT level is a useful marker indi-
cating hepatocellular impairment (15). According to Up-
ToDate ver. 19.3 (UpToDate, Inc. Waltham, MA), HCV infec-
tion with a normal ALT level is deﬁned by the following 
(5); detectable HCV RNA and serum ALT concentration 
that is persistently within the normal range. The deﬁni-
tion of PNALT includes the idea of “persistence”, indicat-
ing maintenance of an ALT level that is below the upper 
limit of the normal value over a long period of time (e.g., 
over a six-month period). However, this deﬁnition has 
varied among the many reports on PNALT, which have 
used diﬀerent periods of observation and upper limits of 
normal ALT that are often set at the highest value of the 
measurement instrument. Moreover, the ALT level varies 
depending on; age, gender, race, and body mass index 
(BMI) (9). Prati et al. investigated 6,835 blood donors with 
ALT levels within the standard range (male: ≤ 40 IU/l, fe-
male: ≤ 30 IU/l) who were negative for infections (HBV, 
HCV, and HIV), had no history of medication, with blood 
glucose, cholesterol, and triglyceride levels lower than 
the upper limits of the standard ranges, and had a BMI < 
25 kg/m2. The ﬁndings showed that 30 and 19 IU/l were ap-
propriate as the upper limits of the normal ALT range in 
males and females, respectively (20). However, according 
to the AASLD Practice guidelines, PNALT is present when 
ALT is measured 2-3 times over 1-6 months and all values 
are < 40 IU/l (9). Thus, the standard ALT level is unclear 
and the criteria for PNALT vary among the diﬀerent re-
ports. Therefore, it is important to pay attention to the 
deﬁnition of a normal ALT level in order to evaluate the 
natural course of HCV carriers with PNALT.
2.3. Clinical Manifestations in HCV Carriers With PNALT
Most HCV carriers with PNALT are discovered inciden-
tally when anti-HCV antibodies are found following a 
blood donation. Most of these patients have asymptom-
atic disease or nonspeciﬁc symptoms including; fatigue, 
weakness, and upper right quadrant pain (20). The fre-
quency and severity of these symptoms have been re-
ported to be similar among anti-HCV positive patients 
with normal serum ALT, mildly elevated values (< 2 times 
normal), and more marked elevation (> 2 times normal) 
(21). In contrast, Jamal et al. have suggested that there is 
a trend towards depression being more common in HCV 
carriers with abnormal ALT compared to those with nor-
mal ALT, although they found that there was no statisti-
cally signiﬁcant diﬀerence in depressive symptoms (20). 
Therefore, depression, though nonspeciﬁc, might  be an 
important clinical marker of a more severe disease.
2.4. Epidemiology, Clinical Course and Management in 
HCV Carriers With PNALT
The ALT level is within the normal range in about 30% 
of HCV carriers and lower than 2-fold the normal upper 
limit in 40% (5, 6), although what constitutes a normal 
ALT value is not completely clear. The frequency of PNALT 
is reported to be higher in HCV genotype 2 carriers and 
females (6, 22). Inﬂammation and ﬁbrosis were shown to 
be histologically mild in approximately 70% of PNALT cas-
es (23); however, ﬁbrosis of stage 2 (F2) or more severe ﬁ-
brosis was noted in 22% of histologically evaluated PNALT 
cases in another report (22). Therefore, severe ﬁbrosis 
can be present in some cases in which their ALT level is 79
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normal. This may be because ALT levels occasionally nor-
malize in patients with liver cirrhosis. The rate of pro-
gression of hepatic ﬁbrosis in patients with chronic hep-
atitis C is reported to be 0.1-0.13 units/year (11, 24). PNALT 
cases have been found to show only a slight histological 
progression over a 10-year follow-up period (25), with a 
reported rate of progression of ﬁbrosis of 0.05 units per 
year (26, 27). These results suggest that ﬁbrosis progress-
es more slowly in PNALT cases. During the long-term fol-
low-up of patients with PNALT, ALT levels rose in 21.5% of 
cases 3-18 months after PNALT was judged to be present 
(6). Platelet count is thought to be a simple marker for 
hepatic ﬁbrosis, and PNALT patients with severe ﬁbrosis 
can be identiﬁed using the criterion of a platelet count ≤ 
150,000/μL. In patients selected using this criterion and 
an ALT level of ≤ 30 IU/L for 5 years, Okanoue et al. showed 
that ALT ≤ 30 IU/L was maintained in only 14% of patients 
(28). In our study, 101 HCV carriers with PNALT (deﬁned 
as ALT ≤ 34 IU/l) were surveyed between 1993 and 2000, 
and ALT levels rose in 31.8% of these patients over a 5-year 
observation period (29). Thus, there is a risk of ALT eleva-
tion in HCV carriers with PNALT, even if the ALT level has 
been continuously normal over several years and if the 
deﬁnition of PNALT includes the platelet count, in addi-
tion to the ALT level. Furthermore, we found that an ALT 
level of 20-34 IU/l [odds ratio (OR): 5.6], a serum ferritin 
level of ≥ 90 ng/ml (OR: 3.1), and a minor allele of the 
HFE gene (H63D, OR: 4.8) were independent risk factors 
for ALT elevation (29). Shiﬀman et al. found that the ALT 
level was maintained at about 20 IU/L in PNALT cases (30). 
Therefore, when the ALT level is ≤ 19 IU/L, it is unlikely to 
rise, and this suggests that 19 IU/L may be an appropriate 
upper limit for ALT in the deﬁnition of PNALT.
2.5. ALT levels in HCV Carriers with End Stage Renal Fail-
ure or HIV Coinfection
The population of patients with ﬁbrosis progression, 
despite having ALT levels within the normal range, typi-
cally includes dialysis patients with HCV infection and 
HCV carriers with HIV coinfection. Dialysis patients are 
a high-risk group for HCV infection, with an HCV preva-
lence of about 13.5% among these patients (31). Dialysis 
patients also generally have a low ALT level, and we also 
found low mean ALT levels of 13.2 and 18.5 IU/l in 238 
HCV-negative and HCV-positive dialysis patients (32). A 
comparison of ALT levels with histologically severe in-
ﬂammation and ﬁbrosis showed that the ALT levels were 
lower in patients with end-stage renal failure who were 
under dialysis, compared to patients with normal renal 
function (33). However, the cause of the low ALT level in 
end-stage renal failure patients is unclear. Among HIV-
infected patients, 25% are reported to be infected with 
HCV (34), and the incidence of ﬁbrosis progression in 
PNALT cases is nearly 2 times higher in patients with HIV-
HCV coinfection than in those with a HCV infection alone 
(35). Thus, although histological progression is generally 
mild in HCV carriers with PNALT, hepatic ﬁbrosis is more 
progressive in those patients with end-stage renal failure 
or an HIV coinfection. 
2.6. Immunopathogenesis of HCV Carriers With PNALT
The mechanism for ALT elevation in HCV carriers is not 
yet fully elucidated, but may be associated with func-
tional abnormalities of the immune cells, such as acti-
vated lymphocytes and NK cells in patients with chronic 
hepatitis C (36, 37). Dendritic cells (DCs) play a central 
role in the activation of immunocytes, and the numbers 
of myeloid DCs (mDCs) and plasmacytaid DCs (pDCs) 
are smaller in patients with chronic hepatitis C than in 
subjects without a HCV infection. A comparison of PNALT 
cases and chronic hepatitis C patients showed no diﬀer-
ence in the number of mDCs or pDCs, but a reduced DC 
function was associated with a higher ALT level (38). In 
contrast, many immunosuppressive regulatory T cells 
Model Name (Reference) Variables Etiology  Fibrosis Stage Cut oﬀ Values  AUROC a
APRI a (44) AST  a, Plt a HCV  Ishak score 0-2
Ishak score 3-6
< 0.5
≥ 1.5
0.80-0.88
FIB-4 (45)  Age, AST, Plt, ALT a HCV/HIV  Ishak score 0-3
Ishak score 4-6
< 1.45
≥ 3.25
0.765
Forns Index (46)  Plt, GGT a, age, cholesterol HCV  F0-1
F2-4
> 4.2
> 6.9
0.81-0.86
Fibro Index (47)  Plt, AST, γ globulin HCV  F0-1
F2-3
≤ 1.25
≥ 2.25
0.83
FibroTest (48)  α2-MC a, α2 globulin (or haptoglobin), 
γ-globulin, apolipoprotein A1, GGT, Total 
bilirubin
HCV F0-1
F2-4
0-0.1
0.6-1.0
0.836-0.870
SHASTA Index (49)  HA a, AST, albumin  HCV/HIV  Ishak score 0-2
Ishak score 3-6
< 0.3
> 0.8
0.878
Hepascore (50)  HA, α2-MC, GGT, age, gender  HCV  F0-2
F3-4
< 0.5
≥ 0.5
0.82-0.90
Table 1. Diagnostic Accuracy of the Models for Predicting Liver Fibrosis Using Examination of Peripheral Blood and Serum Chemistry
a Abbreviations: α2-MC, α2-macroglobulin; ALT, alanine aminotransferase; AUROC, area under receiver operating characteristic curve; AST, aspartate ami-
notransferase APRI, AST-platelet ratio index; GGT, gamma-glutamyltransferase;HA, hyaluronic acid; Plt, platelet80
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(Treg) are present in HCV carriers and the inhibitory 
activity is stronger in PNALT cases than in patients with 
active hepatitis (39). These results indicate that therapy 
to regulate the functional abnormalities of immune 
cells may be valuable in patients with chronic hepatitis 
C in order to reduce the ALT level or hepatic inﬂamma-
tion. In addition, the frequency of DR13 in HCV-infected 
patients with a normal ALT level was signiﬁcantly higher 
than that of HCV-infected patients with elevated ALT (42% 
vs. 4%, Pc < 0.003) (40). Thus, immunological analysis in 
HCV carriers with PNALT may lead to new therapies for 
patients with chronic hepatitis C.
2.7. Noninvasive Evaluation of Fibrosis in HCV Carriers 
With PNALT
In HCV carriers, the risk of HCC increases with the pro-
gression of hepatic ﬁbrosis (41). Liver biopsy is the stan-
dard test for hepatic ﬁbrosis, but it is invasive and causes 
complications at a rate of 1-3% and has a mortality rate of 
1/10000-12000 (42). Moreover, sampling errors leading to 
the underestimation of liver cirrhosis have been report-
ed in 14.5% of cases (43). Noninvasive tests for the evalua-
tion of ﬁbrosis have also been described, these include; 
combinations of peripheral blood and serum chemistry 
tests (44-48) and ﬁbrosis markers (49, 50) (Table 1); elas-
tography using transient elastography (TE FibroScan®) 
and acoustic radiation force impulse (ARFI) (51-57) (Table 
2). Accuracy increases when several tests are used in com-
bination, but the utility of these tests for the evaluation 
of hepatic ﬁbrosis in PNALT cases remains uncertain.
2.8. PNALT and the Risk for HCC in HCV Carriers
Tanaka  et al. investigated HCC development in 1,927 
HCV antibody-positive blood donors and found that 
the incidence of HCC was lower in subjects with a low 
ALT level compared to those with a high ALT level (58). 
In our study, subjects were followed for an average of 8 
years before HCC development, and a strong association 
between the ALT level and HCC development was found, 
with a signiﬁcant association between a 20 IU/L higher 
ALT level and the subsequent incidence of HCC being ob-
served [hazard ratio (HR) = 1.2] (7). The HCC risk was also 
much lower in the PNALT cases than in subjects with a 
persistent abnormal ALT level. Among 551 subjects with 
at least 4 repeated measurements of ALT, those with per-
sistently abnormal ALT levels (n = 118) had a signiﬁcantly 
increased rate of HCC compared to those with persis-
tently normal ALT levels (n = 296) (HR = 23.2) (7). Kumada 
et al. also found that a high ALT level and low platelet 
count were strongly associated with HCC development 
(59). When a low ALT level persists for a prolonged period 
and the platelet count does not decrease, the HCC com-
plication rate may be very low despite the persistence of 
a HCV infection. Collectively, these results show that the 
risk for HCC in subjects with PNALT is low among HCV 
carriers, including patients with chronic hepatitis and 
liver cirrhosis. 
Technique (Reference) Etiology  Fibrosis Stage Cut oﬀ Values AUROC a
TE a (51) HCV  a F ≥ 2
F ≥ 3
F = 4
8.7
9.56
14.52
0.79
0.91
0.99
(52) HCV  F ≥ 2
F ≥ 3
F = 4
7.1
9.5
12.5
0.88
0.95
0.95
(53) CLD a F = 4 14.6 0.95
(54) HCV F ≥ 2
F ≥ 3
F = 4
7.1
9.6
11.6-16.9
0.88
0.90
0.90
(55) HCV F ≥ 1
F ≥ 2
F ≥ 3
F = 4
5.2
8.1
9.6
13.1
0.902
0.941
0.926
0.945
ARFI a (56) HCV F ≥ 2
F ≥ 3
F = 4
1.215
1.54
1.94
0.902
0.993
0.993
(57) CLD a F ≥ 2
F ≥ 3
F = 4
1.34
1.44
1.80
0.94
0.94
0.96
(55) HCV F ≥ 1
F ≥ 2
F ≥ 3
F = 4
1.19
1.34
1.61
2.00
0.709
0.851
0.869
0.911
a Abbreviations: ARFI, acoustic radiation force impulse; AUROC, area under receiver operating characteristic curve; CLD, chronic liver disease; HCV 
Hepatitis C virus; TE, transient elastography
Table 2. Diagnostic Accuracy for Predicting Liver Fibrosis Using Transient Elastography or Acoustic Radiation Force Impulse81
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2.9. Insulin Resistance and Fatty Liver in HCV Carriers 
In liver cirrhosis, insulin sensitivity decreases in pe-
ripheral tissue, for which pancreatic β cells compensate 
through the secretion of excess insulin, inducing hy-
perinsulinemia. Allison et al. found that the rate of dia-
betes complications was higher in liver cirrhosis associ-
ated with a HCV infection, than in that induced by other 
causes (60). The homeostasis model assessment-insulin 
resistance (HOMA-IR) value, which is an index of insulin 
resistance, was found to be signiﬁcantly higher in stage 0 
or 1 chronic hepatitis C patients with mild hepatic ﬁbro-
sis than in healthy subjects, and HOMA-IR served as a pre-
dictor of the progression of hepatic ﬁbrosis (61). Animal 
studies also suggest that the HCV core protein acts on the 
insulin signal transmission pathway and induces insulin 
resistance (62). However, it is unclear whether insulin re-
sistance is present in PNALT cases without hepatic ﬁbro-
sis. A high rate of fat deposition in the liver is caused by 
HCV infection (63), and fatty changes in the liver and in-
sulin resistance are induced in transgenic mice express-
ing the HCV core protein (64). Castera et al. performed a 
liver biopsy at mean intervals of 48 months and observed 
that; male gender, histological stage, and the presence of 
advanced fatty changes were signiﬁcant risk factors in 
promoting hepatic ﬁbrosis, and that fatty change in the 
liver was an independent risk factor in multivariate anal-
ysis (65). Fatty change in the liver is particularly marked 
with genotype 3 viruses (66), and fatty change in the liver 
and insulin resistance have also been associated with the 
negative eﬀects of interferon (IFN)-based therapy (67). 
Thus, insulin resistance and fat deposition in the liver, 
which are associated with hepatic ﬁbrosis, should be less 
severe in PNALT cases compared to HCV patients with 
abnormal ALT, and this may produce a more favorable 
outcome for IFN-based treatment. However, the antiviral 
eﬀect of IFN-based therapy in patients with normal ALT 
is comparable to that for patients with abnormal ALT, re-
gardless of their background advantages (68, 69). There-
fore, further studies of insulin resistance and fat deposi-
tion in the liver are needed in PNALT cases.
3. Results 
3.1. Improved Outcomes With Antiviral Treatment for 
HCV Carriers
Treatment for HCV carriers has improved markedly in 
recent years. Combination therapy with pegylated (PEG) 
interferon (IFN) plus ribavirin achieves a sustained viral 
response (SVR) in approximately 50% of the most intrac-
table genotype 1 patients and high viral load cases. The 
therapeutic eﬀect is determined by; host, viral, and drug 
factors, and host factors include; age, gender, severity 
of hepatic ﬁbrosis, fatty liver changes, and insulin resis-
tance. In 2009, a study performed to identify single nu-
cleotide polymorphisms (SNPs) that determine the eﬀect 
of IFN-based therapy in chronic hepatitis C patients re-
vealed the importance of a SNP near the IL28B gene (70). 
IL28B (also called IFNλ3) is thought to induce antiviral ac-
tivity via the JAK-STAT pathway through phosphorylation 
of STAT1/STAT2 and the subsequent induction of the IFN-
stimulating gene (ISG) (71). In addition to the genotype 
and viral load of HCV RNA, mutations of amino acids in 
the core (72) and the interferon sensitivity-determining 
region (ISDR) (73) have been reported as viral factors 
that determine the eﬀect of IFN-based therapy. In multi-
variate analysis of host and viral factors, a high platelet 
count with mild hepatic ﬁbrosis (F0-1), ≥ 2 ISDR muta-
tions, and the IL28B SNP as the major allele were identi-
ﬁed as factors associated with SVR (74). A lower γGTP lev-
el, and milder inﬂammation, ﬁbrosis, and fatty changes 
were found in patients with the IL-28B SNP as the major 
allele, compared to those with this SNP as the minor al-
lele (74). This suggests that the IL-28B SNP is involved in 
the progression of hepatitis C pathology, as well as in 
the therapeutic eﬀect. These results indicate that SVR is 
likely in PNALT cases. However, there has been no report 
of an IL-28B SNP associated with PNALT. Drug factors that 
inﬂuence the therapeutic eﬀect include; the type of IFN 
and the dose and duration of administration of IFN or 
ribavirin. Novel drugs, such as protease and polymerase 
inhibitors, will soon become available. In combination 
therapy with PEG-IFN, ribavirin and protease inhibitor, 
the overall SVR rate should increase to more than 60% in 
patients with genotype 1b and a high viral load. In addi-
tion, SVR was achieved in 84% of cases with IL-28B SNP as 
the major allele and glutamine or histidine at position 
70 in the core protein, and in 50% of cases with IL-28B SNP 
as the minor allele and arginine at position 70 (75). These 
viral factors and host factors require further investiga-
tion in HCV carriers with PNALT.
3.2. Antiviral Treatment in HCV Carriers With PNALT
The treatment of chronic hepatitis C has improved 
signiﬁcantly over the last few years. Detailed analysis 
of host factors including the IL28B SNP and viral factors 
may improve the accuracy of predicting IFN-based thera-
py eﬀects. For example, this may be based on a prediction 
of the therapeutic eﬀects using data mining of the blood 
test results (74, 76). Establishment of tailor-made thera-
pies may be possible with further investigation of SNPs 
and other data for prediction of IFN-based treatments, 
including those for PNALT cases. Antiviral therapy for 
PNALT cases has been estimated to reduce the prevalence 
of liver cirrhosis and complications by 22% and 16%, re-
spectively, and to decrease the mortality rate by 14% (77). 
The AASLD practice guidelines suggest that a decision to 
use PEG-IFN plus ribavirin therapy should be made based 
on; a histological evaluation, the possibility of adverse ef-
fects, prediction of therapeutic eﬀects, and the presence 
of complications, regardless of the ALT level (9). In ad-
dition, Okanoue et al. reported that the combination of 
ALT and platelet counts is useful for evaluating the ﬁbro-
sis stage in HCV carriers with normal serum ALT levels, 
and that most patients with platelet counts < 150000/82
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μL are candidates for antiviral therapy, especially those 
with ALT levels ≥ 31 U/L when the focus is placed on the 
inhibition of HCC development (27). Puoti et al. have also 
found that a rapid virological response was a predictor 
of sustained response in HCV carriers with PNALT (69). 
Thus, although further studies are required to determine 
whether antiviral therapy should be given in all PNALT 
cases, it seems likely that many HCV carriers with PNALT 
should be treated with IFN-based therapy. Tailor-made 
therapies may also be possible based on the accumula-
tion of data for the prediction of IFN-based treatment ef-
ﬁcacy in PNALT cases.
4. Conclusion
In this review, we have described the clinical character-
istics of HCV carriers with PNALT. For HCV carriers, it is 
important to minimize complications such as liver cir-
rhosis and HCC through careful observation and treat-
ment at the appropriate time. For PNALT cases, the course 
and prognosis should also be monitored and treatment 
should be considered at an early stage.
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